CLINICAL TRIALS PROFILE FOR NYMALIZE
✉ Email this page to a colleague
All Clinical Trials for NYMALIZE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03671525 ↗ | Cognitive Effects of Nimodipine in Patients With Schizophrenia | Suspended | Johns Hopkins University | Early Phase 1 | 2018-10-05 | This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional MRI scan, with the goal of linking brain activity with working memory performance. Investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the A allele for the Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP) (rs1006737) in comparison to the response of G carriers. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NYMALIZE
Condition Name
Clinical Trial Locations for NYMALIZE
Trials by Country
Clinical Trial Progress for NYMALIZE
Clinical Trial Phase
Clinical Trial Sponsors for NYMALIZE
Sponsor Name